The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP‐treated and levodopa‐primed common marmosets
Identifieur interne : 000016 ( Istex/Curation ); précédent : 000015; suivant : 000017The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP‐treated and levodopa‐primed common marmosets
Auteurs : Ronald K. B. Pearce [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Tara Banerji [Royaume-Uni] ; Jorgen Scheel-Krüger [Danemark] ; Peter Jenner [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2002-09.
English descriptors
Abstract
The common marmoset develops motor deficits after MPTP treatment and exhibits dyskinesia after chronic levodopa (L‐dopa) dosing and subsequent re‐challenge with L‐dopa and other dopaminergic agents. We report on the actions of the potent monoamine reuptake blocker brasofensine on motor disability, locomotor activity, and dyskinesia in the 1‐methyl‐4‐1, 2,3,6‐tetrahydropyridine (MPTP) ‐treated marmoset model of Parkinson's disease. Oral administration of brasofensine (0.25, 0.5, 1.0, or 2.5 mg/kg) to MPTP‐treated marmosets produced a long‐lasting, dose‐dependent increase in locomotor activity and reduction in disability scores. In addition, coadministration of the lowest dose of brasofensine (0.25 mg/kg orally) with a threshold oral dose of L‐dopa (2.5 mg/kg) caused a marked increase in locomotor activity, greater than that produced by either drug alone. In other MPTP‐treated marmosets previously primed to exhibit dyskinesia by repeated L‐dopa dosing, brasofensine effectively reversed akinesia with a naturalistic and prolonged motor response without the appearance of dyskinesia or stereotypy. This finding contrasts with the severe dyskinesia, stereotypy, and hyperkinesis produced by equivalent doses of L‐dopa. The ability of brasofensine to produce a prolonged and naturalistic antiparkinsonian response without eliciting dyskinesia after previous L‐dopa priming may relate to actions on D1 receptor‐linked pathways. These findings suggest that monoamine reuptake blockade may be of value in the treatment of Parkinson's disease, both early in the disease course and when L‐dopa–induced dyskinesias complicate treatment. © 2002 Movement Disorder Society
Url:
DOI: 10.1002/mds.10238
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000016
Links to Exploration step
ISTEX:AF5A50DEADD417F68F96E20F0D16EAF3E8EA642ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP‐treated and levodopa‐primed common marmosets</title><author><name sortKey="Pearce, Ronald K B" sort="Pearce, Ronald K B" uniqKey="Pearce R" first="Ronald K. B." last="Pearce">Ronald K. B. Pearce</name><affiliation wicri:level="1"><mods:affiliation>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Charing Cross Hospital, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurology, Charing Cross Hospital, London</wicri:regionArea></affiliation></author><author><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name><affiliation wicri:level="1"><mods:affiliation>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London</wicri:regionArea></affiliation></author><author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name><affiliation wicri:level="1"><mods:affiliation>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London</wicri:regionArea></affiliation></author><author><name sortKey="Banerji, Tara" sort="Banerji, Tara" uniqKey="Banerji T" first="Tara" last="Banerji">Tara Banerji</name><affiliation wicri:level="1"><mods:affiliation>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London</wicri:regionArea></affiliation></author><author><name sortKey="Scheel Ruger, Jorgen" sort="Scheel Ruger, Jorgen" uniqKey="Scheel Ruger J" first="Jorgen" last="Scheel-Krüger">Jorgen Scheel-Krüger</name><affiliation wicri:level="1"><mods:affiliation>NeuroSearch, Smedeland, Glostrup, Denmark</mods:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>NeuroSearch, Smedeland, Glostrup</wicri:regionArea></affiliation></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name><affiliation wicri:level="1"><mods:affiliation>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AF5A50DEADD417F68F96E20F0D16EAF3E8EA642A</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.10238</idno><idno type="url">https://api.istex.fr/document/AF5A50DEADD417F68F96E20F0D16EAF3E8EA642A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000016</idno><idno type="wicri:Area/Istex/Curation">000016</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP‐treated and levodopa‐primed common marmosets</title><author><name sortKey="Pearce, Ronald K B" sort="Pearce, Ronald K B" uniqKey="Pearce R" first="Ronald K. B." last="Pearce">Ronald K. B. Pearce</name><affiliation wicri:level="1"><mods:affiliation>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Charing Cross Hospital, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurology, Charing Cross Hospital, London</wicri:regionArea></affiliation></author><author><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name><affiliation wicri:level="1"><mods:affiliation>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London</wicri:regionArea></affiliation></author><author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name><affiliation wicri:level="1"><mods:affiliation>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London</wicri:regionArea></affiliation></author><author><name sortKey="Banerji, Tara" sort="Banerji, Tara" uniqKey="Banerji T" first="Tara" last="Banerji">Tara Banerji</name><affiliation wicri:level="1"><mods:affiliation>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London</wicri:regionArea></affiliation></author><author><name sortKey="Scheel Ruger, Jorgen" sort="Scheel Ruger, Jorgen" uniqKey="Scheel Ruger J" first="Jorgen" last="Scheel-Krüger">Jorgen Scheel-Krüger</name><affiliation wicri:level="1"><mods:affiliation>NeuroSearch, Smedeland, Glostrup, Denmark</mods:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>NeuroSearch, Smedeland, Glostrup</wicri:regionArea></affiliation></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name><affiliation wicri:level="1"><mods:affiliation>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Pharmacology & Therapeutics, Guy's, King's and St. Thomas’ School of Biomedical Sciences, London</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-09">2002-09</date><biblScope unit="vol">17</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="877">877</biblScope><biblScope unit="page" to="886">886</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">AF5A50DEADD417F68F96E20F0D16EAF3E8EA642A</idno><idno type="DOI">10.1002/mds.10238</idno><idno type="ArticleID">MDS10238</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>L‐dopa</term><term>MPTP</term><term>Parkinson's disease</term><term>dopamine reuptake blockers</term><term>dyskinesia</term><term>marmosets</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The common marmoset develops motor deficits after MPTP treatment and exhibits dyskinesia after chronic levodopa (L‐dopa) dosing and subsequent re‐challenge with L‐dopa and other dopaminergic agents. We report on the actions of the potent monoamine reuptake blocker brasofensine on motor disability, locomotor activity, and dyskinesia in the 1‐methyl‐4‐1, 2,3,6‐tetrahydropyridine (MPTP) ‐treated marmoset model of Parkinson's disease. Oral administration of brasofensine (0.25, 0.5, 1.0, or 2.5 mg/kg) to MPTP‐treated marmosets produced a long‐lasting, dose‐dependent increase in locomotor activity and reduction in disability scores. In addition, coadministration of the lowest dose of brasofensine (0.25 mg/kg orally) with a threshold oral dose of L‐dopa (2.5 mg/kg) caused a marked increase in locomotor activity, greater than that produced by either drug alone. In other MPTP‐treated marmosets previously primed to exhibit dyskinesia by repeated L‐dopa dosing, brasofensine effectively reversed akinesia with a naturalistic and prolonged motor response without the appearance of dyskinesia or stereotypy. This finding contrasts with the severe dyskinesia, stereotypy, and hyperkinesis produced by equivalent doses of L‐dopa. The ability of brasofensine to produce a prolonged and naturalistic antiparkinsonian response without eliciting dyskinesia after previous L‐dopa priming may relate to actions on D1 receptor‐linked pathways. These findings suggest that monoamine reuptake blockade may be of value in the treatment of Parkinson's disease, both early in the disease course and when L‐dopa–induced dyskinesias complicate treatment. © 2002 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000016 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000016 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:AF5A50DEADD417F68F96E20F0D16EAF3E8EA642A
|texte= The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP‐treated and levodopa‐primed common marmosets
}}
| This area was generated with Dilib version V0.6.23. |  |